AgomAb Therapeutics N.V. American Depositary Shares
$13.22-5.2%1Y-4.8%
Mentions · last 7 days
10+14%
Price updated 1d ago·X counts updated 2d ago
AI verdict & sentimentAI analysisGenerated by AI from underlying data
Today's AI verdict on what's driving $AGMB, plus how loud the X conversation is and which way it's leaning.
What it does
Plain-English summary of the business — what they sell and how they make money.
Industry overviewAI analysisGenerated by AI from underlying data
Where Biotechnology sits in its cycle right now — and what that implies for $AGMB.
Biotechnology
No material change from last week — ADA conference oral formulation competition is bifurcating biotech multiples between GLP-1 platform holders and precision oncology innovators.
What this means for $AGMB
Neutral — Clinical-stage biotech developing disease-modifying therapies for chronic fibrotic and inflammatory conditions targeting the HGF/MET pathway; limited read-through from biotechnology macro dynamics to this specific revenue mix.
Top industry ETF
$IBBiShares Biotechnology ETF
+12.1%YTD
+44.4%1Y
Fundamentals & catalyst
Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.
Key ratios
P/E
-22.8How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.ROIC
-20.9%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.Op margin
0.0%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.FCF yield
-3.4%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).P/S
0.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.ROE
-21.0%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.Gross margin
0.0%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.D/E
0.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.Past earnings
QuarterReportedActualEstimateSurprise
Q2 2026Aug 6, 2026$-0.91$-0.38-137.6%
Q1 2026Jun 3, 2026$-0.45$-0.42-6.8%
Q4 2025Feb 25, 2026$-0.36$-0.52+30.3%
Next earningsWed, Mar 3·consensus EPS $-1.00
Quarterly trend
QuarterRevenueYoYGrossOpEPSFCF
Q4 FY25$0———$-0.36$-13.2M
Q4 FY24$0———$-0.32$-12.8M
Forward consensus
FYRevenueRangeEPSRangeAnalysts
FY26$683K$683K – $683K-$1.80-$2.02 – -$1.594
FY27$820K$820K – $820K-$2.10-$2.44 – -$1.524
FY28$902K$902K – $902K-$2.21-$2.65 – -$1.844
FY29$1.3M$1.3M – $1.3M-$2.23-$2.23 – -$2.233
FY30$1.3M$1.3M – $1.3M-$2.36-$2.36 – -$2.363
Setup & momentum
Volume, range, and moving-average position — the technical setup driving short-term moves.
Right now
Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.5×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.—Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+5.9%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.—Latest close vs the 200-day simple moving average. Positive = long-term trend is up.
Float & profile
FloatLow float · 36.3M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today0.1% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β1.645-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.
SEC filings
Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.
Recent material filings
+ 17 other (6 6-Ks · 5 13Gs · 3 3s · 1 20-F) in window
Recent news
Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.
Agomab Announces Proposed Appointments of Marino Garcia and Dr. Naimish Patel to Board of DirectorsAgomab Reports Half Year 2026 Financial Results and Confirms 2026 OutlookAgomab Announces Design of NOV-ERA Phase 2b Study with Ontunisertib in Fibrostenosing Crohn's DiseaseAgomab Announces Design of NOV-ERA Phase 2b Study with Ontunisertib in Fibrostenosing Crohn’s DiseaseAgomAb Therapeutics: High Risk, High Reward Stock
More in Biotechnology
Peers in the same group — one click to compare setups, fundamentals, and chatter.
Voices on X · last 7 days
No standout posts about $AGMB on X in the last 7 days.